Monirul, S.; Rigal, M.; Chouahnia, K.; Le Jouan, M.; Apparuit, M.; Paix, A.; Jacolot, A.; Zelek, L.; Duchemann, B.
Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer. Vaccines 2020, 8, 730.
https://doi.org/10.3390/vaccines8040730
AMA Style
Monirul S, Rigal M, Chouahnia K, Le Jouan M, Apparuit M, Paix A, Jacolot A, Zelek L, Duchemann B.
Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer. Vaccines. 2020; 8(4):730.
https://doi.org/10.3390/vaccines8040730
Chicago/Turabian Style
Monirul, Sanjana, Marthe Rigal, Kader Chouahnia, Mélisande Le Jouan, Maxime Apparuit, Adrien Paix, Anne Jacolot, Laurent Zelek, and Boris Duchemann.
2020. "Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer" Vaccines 8, no. 4: 730.
https://doi.org/10.3390/vaccines8040730
APA Style
Monirul, S., Rigal, M., Chouahnia, K., Le Jouan, M., Apparuit, M., Paix, A., Jacolot, A., Zelek, L., & Duchemann, B.
(2020). Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer. Vaccines, 8(4), 730.
https://doi.org/10.3390/vaccines8040730
